MENU
+Compare
LFCR
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$7.23
Change
+$0.16 (+2.26%)
Capitalization
176.87M

LFCR stock forecast, quote, news & analysis

LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for LFCR with price predictions
Dec 20, 2024

LFCR's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for LFCR moved out of overbought territory on November 21, 2024. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for LFCR turned negative on December 04, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on December 20, 2024. You may want to consider a long position or call options on LFCR as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for LFCR moved above the 200-day moving average on December 04, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LFCR advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

LFCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 177 cases where LFCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LFCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.789) is normal, around the industry mean (57.958). P/E Ratio (0.000) is within average values for comparable stocks, (89.727). Projected Growth (PEG Ratio) (2.661) is also within normal values, averaging (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (1.680) is also within normal values, averaging (19.472).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 3.53B. The market cap for tickers in the group ranges from 246 to 77.48B. ZTS holds the highest valuation in this group at 77.48B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was -10%. PRFX experienced the highest price growth at 70%, while MSTH experienced the biggest fall at -48%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 30%. For the same stocks of the Industry, the average monthly volume growth was 111% and the average quarterly volume growth was 53%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 71
Price Growth Rating: 65
SMR Rating: 84
Profit Risk Rating: 91
Seasonality Score: 34 (-100 ... +100)
View a ticker or compare two or three
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a manufacturer of polymer products for food and agricultural products, medical devices and licensed partner applications

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Industrial Specialties
Address
3515 Lyman Boulevard
Phone
+1 952 368-4300
Employees
459
Web
https://www.lifecore.com